Limit search to available items
Book Cover

Title Antibody-drug conjugates and immunotoxins : from pre-clinical development to therapeutic applications / Gail Lewis Phillips, editor
Published New York : Springer, ©2013


Description 1 online resource
Series Cancer drug discovery and development
Cancer drug discovery and development.
Contents Introduction and Development Perspectives -- Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins / Pamela A. Trail -- Antibody-Drug Conjugate Development / Aakanksha Khandelwal, Haleh Saber, Marjorie A. Shapiro, Hong Zhao -- Development of Antibody-Drug Conjugates -- Assay Methodologies and Challenges / Katherine R. Kozak, Helga Raab -- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates / Sandhya Girish, Manish Gupta -- Predictive Biomarkers for Antibody-Drug Conjugates / David Dornan, Jeff Settleman -- Selection of Cytotoxic Agents -- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates / Wayne C. Widdison, Ravi V.J. Chari -- Linker Technology and Impact of Linker Design on ADC Properties / Victor S. Goldmacher, Rajeeva Singh, Thomas Chittenden, Yelena Kovtun -- Antibody-Drug Conjugates for Hematologic Malignancies -- Antibody-Drug Conjugates for the Treatment of B-Cell Malignancies / Andrew G. Polson -- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies / John M. Lambert, Veronique Blanc, Nathalie Le Bail, Anne Bousseau -- Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies / Andres Forero, Christos Vaklavas, Albert F. LoBuglio -- Antibody-Drug Conjugates for Solid Tumors -- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer / Hope S. Rugo, Ian E. Krop, Yu-Waye Chu -- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) / Christos Vaklavas, Albert F. LoBuglio, Mansoor Saleh, Michael Yelin, Andres Forero -- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer / Douglas Leipold, William G. Mallet -- EphA2 Immunoconjugate / Zhan Xiao, Dowdy Jackson, David A. Tice -- Anti-PSMA Antibody-Drug Conjugates and Immunotoxins / Philipp Wolf -- Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine / John M. Lambert, James O'Leary, Kathleen R. Whiteman, Victor S. Goldmacher -- Metabolism -- Studies on the Metabolism of Antibody-Drug Conjugates / Xiuxia Sun, Hans Erickson -- Immunotoxins -- Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu / Yu Cao, Michael G. Rosenblum -- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors / Joycelyn Entwistle, Mark Kowalski, Jennifer Brown, Jeannick Cizeau, Glen C. MacDonald
Summary The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer
Bibliography Includes bibliographical references and index
Notes English
Print version record
In Springer eBooks
Subject Antibody-drug conjugates.
Antibody-toxin conjugates.
Drug interactions.
Drug Combinations
MEDICAL -- Pharmacology.
Drug interactions
Antibody-drug conjugates
Antibody-toxin conjugates
medicines (material)
Form Electronic book
Author Phillips, Gail Lewis
ISBN 9781461454564